Metabolic interactions of magnolol with cytochrome P450 enzymes: uncompetitive inhibition of CYP1A and competitive inhibition of CYP2C

References

• Chang J. Medicinal herbs: drugs or dietary supplements? Biochem Pharmacol 2000;59:211–19
   PubMed Web of Science ®Google Scholar
• Kennedy DA, Seely D. Clinically based evidence of drug-herb interactions: a systematic review. Expert Opin Drug Saf 2010;9:79–124
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Tan QR, Tong Y, et al. An epidemiological study of concomitant use of Chinese medicine and antipsychotics in schizophrenic patients: implication for herb-drug interaction. PLoS One 2011;6:e17239
   Google Scholar
• Mahat B, Chae JW, Baek IH, et al. Biopharmaceutical characterization of decursin and their derivatives for drug discovery. Drug Dev Ind Pharm 2013;39:1523–30
   PubMed Web of Science ®Google Scholar
• Jeong HU, Kong TY, Kwon SS, et al. Effect of honokiol on cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules 2013;18:10681–93
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim JE, Kim DD, et al. In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications. Drug Dev Ind Pharm 2014;40:989–98
   PubMed Web of Science ®Google Scholar
• Li Q, Liu Y, Jiao J, et al. Assessment of effects of IR and IPC on activities of cytochrome P450 isozymes in rats by a five-drug cocktail approach. Drug Dev Ind Pharm 2014;40:157–62
   PubMed Web of Science ®Google Scholar
• Ahmed IS, Hassan MA, Kondo T. Effect of lyophilized grapefruit juice on P-glycoprotein-mediated drug transport in-vitro and in-vivo. Drug Dev Ind Pharm 2015;41:375–81
   PubMed Web of Science ®Google Scholar
• Borrelli F, Izzo AA. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J 2009;11:710–27
   PubMed Web of Science ®Google Scholar
• Chen XW, Serag ES, Sneed KB, et al. Clinical herbal interactions with conventional drugs: from molecules to maladies. Curr Med Chem 2011;18:4836–50
   PubMed Web of Science ®Google Scholar
• He SM, Yang AK, Li XT, et al. Effects of herbal products on the metabolism and transport of anticancer agents. Expert Opin Drug Metab Toxicol 2010;6:1195–213
   PubMed Web of Science ®Google Scholar
• Khan AW, Kotta S, Ansari SH, et al. Enhanced dissolution and bioavailability of grapefruit flavonoid Naringenin by solid dispersion utilizing fourth generation carrier. Drug Dev Ind Pharm 2015;41:772–9
   PubMed Web of Science ®Google Scholar
• Mason P. Important drug-nutrient interactions. Proc Nutr Soc 2010;69:551–7
   PubMed Web of Science ®Google Scholar
• Surya Sandeep M, Sridhar V, Puneeth Y, et al. Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. Drug Dev Ind Pharm 2014;40:1371–7
   PubMed Web of Science ®Google Scholar
• Joo J, Liu K-H. Inhibitory effect of honokiol and magnolol on cytochrome P450 enzyme activities in human liver microsomes. Mass Spectrom Lett 2013;4:34–7
   Google Scholar
• Lin SP, Hou YC, Liao TY, et al. Enhancing the bioavailability of magnolol in rabbits using melting solid dispersion with polyvinylpyrrolidone. Drug Dev Ind Pharm 2014;40:330–7
   PubMed Web of Science ®Google Scholar
• Chen YH, Lin FY, Liu PL, et al. Antioxidative and hepatoprotective effects of magnolol on acetaminophen-induced liver damage in rats. Arch Pharm Res 2009;32:221–8
   PubMed Web of Science ®Google Scholar
• Lee DH, Szczepanski MJ, Lee YJ. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem 2009;106:1113–22
   PubMed Web of Science ®Google Scholar
• Park J, Lee J, Jung E, et al. In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp. Eur J Pharmacol 2004;496:189–95
   PubMed Web of Science ®Google Scholar
• Zhu L, Ge G, Liu Y, et al. Potent and selective inhibition of magnolol on catalytic activities of UGT1A7 and 1A9. Xenobiotica 2012;42:1001–8
   PubMed Web of Science ®Google Scholar
• Zhu L, Ge G, Zhang H, et al. Characterization of hepatic and intestinal glucuronidation of magnolol: application of the relative activity factor approach to decipher the contributions of multiple UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 2012;40:529–38
   PubMed Web of Science ®Google Scholar
• Greenberg M, Urnezis P, Tian M. Compressed mints and chewing gum containing magnolia bark extract are effective against bacteria responsible for oral malodor. J Agric Food Chem 2007;55:9465–9
   PubMed Web of Science ®Google Scholar
• Yoon IS, Choi MK, Kim JS, et al. Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. Xenobiotica 2011;41:243–51
   PubMed Web of Science ®Google Scholar
• Bowalgaha K, Elliot DJ, Mackenzie PI, et al. S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 2005;60:423–33
   PubMed Web of Science ®Google Scholar
• Khojasteh SC, Prabhu S, Kenny JR, et al. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet 2011;36:1–16
   PubMed Web of Science ®Google Scholar
• Lewis DF. Guide to cytochromes: structure and function. Boca Raton (FL): CRC Press; 1996
   Google Scholar
• Wang L, Bao SH, Pan PP, et al. Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Dev Ind Pharm 2014. [Epub ahead of print]. Available from: http://informahealthcare.com/doi/abs/10.3109/03639045.2014.950274 [last accessed 19 Jun 2015]
   Web of Science ®Google Scholar
• Murakami Y, Shimizu Y, Ogasawara A, et al. Interspecies comparison of hepatic metabolism of six newly synthesized retinoid X receptor agonistic compounds possessing a 6-[N-ethyl-N-(alkoxyisopropylphenyl)amino]nicotinic acid skeleton in rat and human liver microsomes. Drug Dev Ind Pharm 2014;40:1065–71
   PubMed Web of Science ®Google Scholar
• Zhang YH, Zhang YJ, Guo YL, et al. Astragaloside IV inhibited the activity of CYP1A2 in liver microsomes and influenced theophylline pharmacokinetics in rats. J Pharm Pharmacol 2013;65:149–55
   PubMed Web of Science ®Google Scholar
• Zhao K, Ding M, Cao H, et al. In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates. J Pharm Pharmacol 2012;64:1445–51
   PubMed Web of Science ®Google Scholar
• Yeung JH, Or PM. Polysaccharide peptides from Coriolus versicolor competitively inhibit model cytochrome P450 enzyme probe substrates metabolism in human liver microsomes. Phytomedicine 2012;19:457–63
   PubMed Web of Science ®Google Scholar
• Jurica J, Konecny J, Zahradnikova LZ, et al. Simultaneous HPLC determination of tolbutamide, phenacetin and their metabolites as markers of cytochromes 1A2 and 2C6/11 in rat liver perfusate. J Pharm Biomed Anal 2010;52:557–64
   PubMed Web of Science ®Google Scholar
• Basha SJ, Naveed SA, Tiwari NK, et al. Concurrent determination of ezetimibe and its phase-I and II metabolites by HPLC with UV detection: quantitative application to various in vitro metabolic stability studies and for qualitative estimation in bile. J Chromatogr B Analyt Technol Biomed Life Sci 2007;853:88–96
   PubMed Web of Science ®Google Scholar
• Sun Y, Takaba K, Kido H, et al. Simultaneous determination of arylpropionic acidic non-steroidal anti-inflammatory drugs in pharmaceutical formulations and human plasma by HPLC with UV detection. J Pharm Biomed Anal 2003;30:1611–19
   PubMed Web of Science ®Google Scholar
• Tsai TH, Chou CJ, Chen CF. Disposition of magnolol after intravenous bolus and infusion in rabbits. Drug Metab Dispos 1994;22:518–21
   PubMed Web of Science ®Google Scholar
• Knutter I, Kottra G, Fischer W, et al. High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos 2009;37:143–9
   PubMed Web of Science ®Google Scholar
• Han SY, Yoon I, Chin YW, et al. Pharmacokinetic interaction between metoprolol and SP-8203 in rats: competitive inhibition for the metabolism of metoprolol by SP-8203 via hepatic CYP2D subfamily. Xenobiotica 2012;42:1017–27
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhu M, Humphreys WG. Drug metabolism in drug design and development. Hoboken (NJ): John Wiley & Sons; 2007
   Google Scholar
• Fisher MB, Campanale K, Ackermann BL, et al. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 2000;28:560–6
   PubMed Web of Science ®Google Scholar
• Lin SP, Tsai SY, Lee Chao PD, et al. Pharmacokinetics, bioavailability, and tissue distribution of magnolol following single and repeated dosing of magnolol to rats. Planta Med 2011;77:1800–5
   PubMed Web of Science ®Google Scholar